Caribou Biosciences, Inc. (CRBU)
NASDAQ NMS - GLOBAL MARKET · Biotechnology
$0.49-0.04 (-7.62%)Quote refreshed
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Market Cap
$52.8M
P/E (TTM)
—
EPS
—
Div Yield
—
52W Range
—
Beta
—
Company overview
No company overview is available for Caribou Biosciences, Inc. yet.
Peers in Biotechnology
All in industry →VRTX#1
Vertex Pharmaceuticals Incorporated
$113.64B+0.64%
REGN#2
Regeneron Pharmaceuticals, Inc.
$78.80B-0.99%
ARGX#3
argenx SE
$49.22B+1.97%
ALNY#4
Alnylam Pharmaceuticals, Inc.
$42.61B-1.82%
ONC#5
BeOne Medicines AG
$34.75B+0.39%
INSM#6
Insmed Incorporated
$34.45B-0.37%
RPRX#7
Royalty Pharma plc
$27.86B+0.84%
BNTX#8
BioNTech SE
$23.26B-0.11%
ROIV#9
Roivant Sciences Ltd.
$20.38B+1.10%
MRNA#10
Moderna, Inc.
$20.34B-1.57%
Recent press releases
Caribou Biosciences, Inc. has not issued a press release in this window.
SEC filings
All filings →Caribou Biosciences, Inc. has not filed an SEC document in this window.
Insider trades
All insider trades →Caribou Biosciences, Inc. has no reported insider trades in the last 90 days.
Institutional holders
All holders →As of 2025-12-31 · prior 2025-09-30
767,002 sh-76.2%
Pfizer Inc$7.5M
4,690,431 sh0.0%
2,503,302 sh-18.4%
VANGUARD GROUP INC$6.8M
4,304,198 sh+1.8%
957,787 sh-29.5%
1,006,010 sh-16.9%
MARSHALL WACE, LLP$1.4M
881,105 sh+600.1%
1,115,700 sh-9.1%
People at Caribou Biosciences, Inc.
All people →Quarterly financials
Full financials →Revenue trend
03/25
$2.4M
NI -$40.0M
06/25
$1.0M
NI -$54.1M
09/25
$2.2M
NI -$27.5M
RevenueNI = Net Income
EPS trend (diluted)
Latest: $-0.30
Prior: $-0.58
Revenue sparkline